Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial.

Yu Sunakawa,J Usher,Y. Jaimes,Akihito Tsuji,Manabu Shiozawa,Takanori Watanabe,Hironaga Satake,Hirofumi Ota,Mitsugu Kochi,Hisatsugu Ohori,Dai Manaka,Masato Matsuura,Masahiro Takeuchi,Peter V. Danenberg,Masashi Fujii,Wataru Ichikawa,Heinz-Josef Lenz,Kathleen D. Danenberg

Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial.

2019

Yu Sunakawa
J Usher
Y. Jaimes
Akihito Tsuji
Manabu Shiozawa
Takanori Watanabe
Hironaga Satake
Hirofumi Ota
Mitsugu Kochi
Hisatsugu Ohori
Dai Manaka
Masato Matsuura
Masahiro Takeuchi
Peter V. Danenberg
Masashi Fujii
Wataru Ichikawa
Heinz-Josef Lenz
Kathleen D. Danenberg

TPS3621Background: A randomized phase II trial, DEEPER (JACCRO CC-13) [NCT02515734], is on-going to evaluate FOLFOXIRI plus cetuximab (cet) vs. FOLFOXIRI plus bevacizumab (bev) in terms of depth of...

Keywords:

RNA
Colorectal cancer
Oncology
Pathology
Biomarker (medicine)
Internal medicine
Medicine
Bevacizumab
treatment response
FOLFOXIRI
Cetuximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations